Indolepropionamide

IPAM — indole-3-propionamide; the amide of the gut metabolite indole-3-propionic acid (IPA). NOT Ipamorelin

Indolepropionamide (IPAM — indole-3-propionamide; the amide of the gut metabolite indole-3-propionic acid (IPA). NOT Ipamorelin) is a longevity & bioregulators research compound. Two molecules one atom apart. Indole-3-propionic acid (IPA, C11H11NO2, 189.21 g/mol) is a gut-bacterial tryptophan metabolite: its production in mice is completely dependent on gut flora and can be established by colonizing them with Clostridium sporogenes. Indolepropionamide (IPAM, C11H12N2O, 188.23 g/mol) is the same skeleton with the terminal carboxylic acid replaced by a primary amide, which removes the negative charge the acid carries at blood pH. The acid's published mechanism is radical chemistry — hydroxyl-radical scavenging that exceeded melatonin's in kinetic competition — plus ligand activity at the pregnane X receptor, which is a route to its gut-barrier effects. The amide's own paper argues something different: that it binds the rate-limiting component of oxidative phosphorylation in complex I of the mitochondrial respiratory chain and stabilizes energy metabolism, reducing ROS production by cutting electron leakage rather than by scavenging radicals. Whether an oral amide dose is hydrolyzed to the acid — the assumption the whole product rests on — has never been measured.

How Indolepropionamide works

Two molecules one atom apart. Indole-3-propionic acid (IPA, C11H11NO2, 189.21 g/mol) is a gut-bacterial tryptophan metabolite: its production in mice is completely dependent on gut flora and can be established by colonizing them with Clostridium sporogenes. Indolepropionamide (IPAM, C11H12N2O, 188.23 g/mol) is the same skeleton with the terminal carboxylic acid replaced by a primary amide, which removes the negative charge the acid carries at blood pH. The acid's published mechanism is radical chemistry — hydroxyl-radical scavenging that exceeded melatonin's in kinetic competition — plus ligand activity at the pregnane X receptor, which is a route to its gut-barrier effects. The amide's own paper argues something different: that it binds the rate-limiting component of oxidative phosphorylation in complex I of the mitochondrial respiratory chain and stabilizes energy metabolism, reducing ROS production by cutting electron leakage rather than by scavenging radicals. Whether an oral amide dose is hydrolyzed to the acid — the assumption the whole product rests on — has never been measured.

Proposed benefits

Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.

Where to get Indolepropionamide

The evidence for Indolepropionamide

Graded by what exists behind each claim.

✅ Clinically validated

• No human trial of indole-3-propionamide exists, and no human pharmacokinetic study of it exists in any species. Its entire published record as a substance is a single 2010 paper in isolated rodent mitochondria and in rotifers. Everything else sold under the IPAM name borrows the literature of a different molecule.
• The compound it is constantly confused with is not the acid — it is Ipamorelin, a growth-hormone secretagogue with no chemical or pharmacological relationship to this at all. The names differ by three letters and the molecules have nothing in common.

📊 Correlative data

• Indole-3-propionic ACID — the free acid, not the amide — is associated with markedly lower incident type-2 diabetes in the Finnish Diabetes Prevention Study, followed for 15 years, with the association replicated in two further cohorts. That is the strongest human evidence anywhere near this compound, and it is an association with a metabolite the body's own bacteria make, not a trial of anything anybody swallowed.
• Serum levels of the acid track dietary fiber intake and gut microbiome composition, with a dose-response demonstrated across whole-grain intakes in a controlled feeding study. The obvious confound is the obvious one: a person with more of this metabolite is a person eating more fiber.
• The acid is absent from germ-free animals and is produced by *Clostridium sporogenes* and relatives through a defined aromatic-amino-acid pathway — so an endogenous supply already exists and varies with the microbiome rather than with intake.

🧪 Theoretical / extrapolated

• The acid is a ligand at the pregnane X receptor and the aryl hydrocarbon receptor, which is the plausible route to the gut-barrier effects reported for it, and the mechanism a supplement would have to reproduce to matter.
• The mechanism's own best paper argues against a daily capsule. Acute exposure raised maximal mitochondrial respiration by about 21%; chronic exposure lowered it by about 19%, reproduced in human hepatic and endothelial cells. A supplement taken every day is the chronic arm of that experiment.
• Whether an oral dose of the amide raises serum concentrations of the acid has never been measured in anything. One LC-MS/MS draw would settle it, and until somebody runs it the entire case for buying the amide rather than eating fiber rests on an untested assumption.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Indolepropionamide actually does

Get the two molecules straight first, because almost everything written about this product is written about the other one. Indole-3-propionic acid (IPA) is an indole ring carrying a three-carbon chain ending in a carboxylic acid: C₁₁H₁₁NO₂, 189.21 g/mol. Indole-3-propionamide (IPAM) is the same skeleton with that –COOH replaced by –CONH₂: C₁₁H₁₂N₂O, 188.23 g/mol. One oxygen out, one nitrogen and one hydrogen in.

That group is not a detail, it is the charge. A carboxylic acid with a pK_a in the low single figures is essentially fully deprotonated at blood pH, so IPA circulates as an anion. A primary amide does not ionize in that range, so IPAM circulates neutral — and charge is what sets protein binding, passive membrane permeability and renal handling. That is chemistry, not a measurement: nobody has published a side-by-side distribution study of the two.

There is a published reason to expect the swap to matter at exactly this position. Jasiewicz 2021 synthesized fifteen C-3 substituted indoles and ran three in vitro antioxidant assays. Their conclusion is that activity “strongly depends on the type of the substituent directly connected to the methylene group at the C-3 position”, with indolyl radical stabilization and an unsubstituted indole nitrogen both mandatory. Our two molecules keep that free NH; what differs is precisely the substituent that paper says governs the answer. It did not test IPA against IPAM, so this is a reason to check, not a result.

Each molecule's own paper claims a different mechanism. For the acid, Chyan 1999 is radical chemistry: in kinetic competition with free-radical-trapping agents, IPA's capacity to scavenge hydroxyl radicals exceeded that of melatonin, and unlike other antioxidants it “was not converted to reactive intermediates with pro-oxidant activity”. For the amide, Poeggeler 2010 argues that IPAM “binds to the rate-limiting component of oxidative phosphorylation in complex I of the respiratory chain and acts as a stabilizer of energy metabolism, thereby reducing ROS production”. Stopping the leak, not mopping it up. Poeggeler and Pappolla are authors on both papers, eleven years apart, and the abbreviation on the vendor's label traces back to the 2010 one.

The identity problem a certificate of analysis will not solve. Monoisotopic masses are 189.0790 Da for the acid and 188.0950 Da for the amide, 0.984 Da apart — but the amide's first ¹³C isotopologue lands at 189.0983 Da, just 0.019 Da from the acid's monoisotopic peak, so separating those two signals needs a resolving power around 10,000. That arithmetic is done here rather than read off a paper, and its point is practical: a nominal-mass certificate reporting “189” is consistent with either molecule, and nobody in this category publishes a high-resolution spectrum or an NMR.

Finally, the name collides with a different drug entirely. Ipamorelin is an injected pentapeptide growth-hormone secretagogue acting at the ghrelin receptor. It shares four letters with this product and nothing else.

Cell, rodent, human — and where it stops

Where the acid comes from, which is the strangest thing about it. Wikoff 2009 compared plasma from germ-free mice against conventional animals by mass spectrometry and found IPA production “completely dependent on the presence of gut microflora” and able to be established by colonization with Clostridium sporogenes. No bacteria, no IPA. This is not something the body makes; it is something a resident organism makes out of your dietary tryptophan.

Then the pathway was taken apart genetically, which is the cleanest causal step in the file. Dodd 2017 characterized the C. sporogenes route that metabolizes tryptophan, phenylalanine and tyrosine into twelve compounds, nine of which accumulate in host serum. Manipulating the bacterium's genes modulated those serum levels in gnotobiotic mice, “and show that in turn this affects intestinal permeability and systemic immunity”.

A receptor the acid demonstrably engages. Venkatesh 2014 identified IPA, in the context of indole, as a ligand for the pregnane X receptor in vivo: it downregulated enterocyte TNF-α and upregulated junctional protein-coding mRNAs, while PXR-deficient mice showed a leaky-gut phenotype corrected by additionally deleting TLR4.

Cells. Chyan 1999 reported that IPA completely protected primary neurons and neuroblastoma cells against oxidative damage and death from three separate insults — amyloid-beta, inhibition of superoxide dismutase, and hydrogen peroxide. Culture dishes; no animal, no person.

Humans, and this is the strongest part of the file. de Mello 2017 took the Finnish Diabetes Prevention Study and compared 96 people who developed type 2 diabetes with 104 who did not over 15 years, all with impaired glucose tolerance at baseline. Higher indolepropionic acid was associated with a reduced likelihood of type 2 diabetes, replicated in one further Finnish and one Swedish population; among the non-converters it tracked with better insulin secretion and correlated negatively with low-grade inflammation. The authors call it “a potential biomarker” that “may mediate its protective effect by preservation of beta-cell function”.

The word carrying the weight there is ‘biomarker’. Nobody gave anybody IPA; these are associations with an endogenously produced metabolite. Sehgal 2022 states the confound outright — levels “heavily depend on the diet, particularly dietary fiber, and show huge variations among individuals”. A low serum IPA is a reasonable proxy for a low-fiber diet and a particular gut community, and both are themselves candidate causes of the diabetes. No trial has given IPA, or the amide, to humans and measured incident diabetes.

The second obstacle is the one specific to what is in the bottle. Everything above is the acid. The amide's entire published record as a substance is Poeggeler 2010, in which IPAM reversed the age-dependent decline of mitochondrial energetic capacity and increased rotifer lifespan — a rotifer being a millimeter-scale aquatic invertebrate. No mouse lifespan study, no mammalian in vivo study, no human study. The only other current literature using the string “1H-indole-3-propionamide” is a medicinal chemistry program building Nav1.7 sodium-channel blockers for pain Wang 2025. So the chain for this product reads cell → invertebrate → stop, with a rich human literature sitting one functional group away.

Indolepropionamide pharmacokinetics — how much of it actually gets in

Start with the blank, because the blank is the finding. No pharmacokinetic study of indole-3-propionamide has been published in any species: no absorption fraction, no C_max, no half-life, no clearance route. Not poorly characterized — absent. What follows is the arithmetic that bounds the exposure, which is the honest substitute for a number nobody has measured.

What should degrade it, and why that question is the whole product. IPAM is a primary carboxamide, and the standard metabolic fate of a primary amide is hydrolysis — by an amidase or related hydrolase in the gut wall, the gut flora or the liver — releasing the carboxylic acid and ammonia. If that happens, indole-3-propionamide is a prodrug of indole-3-propionic acid and every human association above becomes relevant to the capsule. If it does not, the capsule is a neutral lipophilic indole with one rotifer paper behind it. Nobody has published the hydrolysis rate, the enzyme responsible, or a serum IPA curve after an oral IPAM dose. The acid's own downstream handling is the ordinary small-organic-acid route — conjugation, including glucuronidation, then renal excretion.

The oral barrier cuts both ways. An ionized carboxylate crosses membranes poorly by passive diffusion; a neutral amide of the same skeleton is more lipophilic and usually permeates better. So the amide has the better absorption argument and the worse evidence argument, and the two only reconcile if first-pass metabolism turns one into the other. The nearest published oral bioavailability figure for anything called an indole-3-propionamide is F = 20.29%, for WN2-R in Wang 2025 — a decorated Nav1.7 inhibitor built on the scaffold, not this molecule. It is quoted only to show how far you have to reach for a number.

The one real dose-response in the literature was neither swallowed nor injected. Gesper 2021 perfused isolated mouse hearts with the acid and got contractility rising dose-dependently from +26.8 ± 11.6% at 1 µM to +93.6 ± 14.4% at 100 µM. An isolated perfused heart has no gut and no liver: the concentration was applied to the organ. There is no injectable presentation of either molecule and no published injected dose in a live animal, so those concentrations have never been shown to be reachable by mouth in anything.

And the counterfactual nobody prices in: your gut is already making the acid. Supply is dietary and microbial Wikoff 2009, and it responds to food. Koistinen 2024 fed 68 healthy volunteers whole-grain wheat or rye at 48 g/day and then 96 g/day, four weeks each, and reported the higher intake shifting the metabolite profile — microbial metabolites included — more with rye than wheat, several microbially-linked metabolites rising linearly between the two intakes. That abstract does not name IPA, so this is not a measurement of this molecule; it is evidence the production route has a real dose-response you can drive with breakfast.

What would have to be true, and how you would know it was not

Four predictions. The first is the one this product stands or falls on, the fourth points against it, and each names something you can actually draw.

1. If the amide is a prodrug, serum indole-3-propionic acid has to rise after an oral dose. That is the load-bearing assumption of the whole page and it has never been tested. It is one measurement: serum IPA before, and 1–4 hours after, a single oral dose, by LC-MS/MS. If serum IPA does not move, every human number on this page stops applying to the capsule and what remains is one rotifer study. Order a high-resolution method — per the arithmetic above, separating the amide's ¹³C peak from the acid's monoisotopic peak needs about 10,000 resolving power, which a nominal-mass assay does not have.

2. If the antioxidant claim is real in a person, an oxidative stress marker moves before anything else does. The acid's case is radical chemistry Chyan 1999, and the cheapest human readout for that is F2-isoprostane in urine, normalized to creatinine — the closest thing to a direct measurement of the claimed mechanism available outside a laboratory. No published study has run it on either molecule.

3. The metabolic prediction, and it should be small and slow. The human signal is an association over 15 years de Mello 2017. If a capsule reproduces any fraction of it, the order of movement is fasting insulin, then C-peptide as the direct beta-cell readout the authors' own mechanism implies, then HbA1c, with hs-CRP alongside because the same paper reported IPA correlating negatively with low-grade inflammation. The retest windows are not optional: HbA1c integrates roughly 90 days, so a value at six weeks means nothing, while fasting insulin can move inside a month. The honest prior is that nothing moves, because the exposure being imitated is a lifetime of a fiber-fed microbiome rather than eight weeks of a pill.

4. THE PREDICTION THAT CUTS AGAINST THE PRODUCT, and it comes from the mechanism's own best paper rather than from a complaint. Gesper 2021 screened 25 microbial metabolites for effects on mitochondrial respiration in HL-1 cardiomyocytes. IPA was the hit — and the sign of the effect reversed with duration. Acute treatment raised maximal mitochondrial respiration +21.5 ± 7.8% (p < 0.05); chronic exposure produced mitochondrial dysfunction, −18.9 ± 9.1% (p < 0.001), reproduced in human hepatic and endothelial cells. A daily capsule is chronic exposure by definition, so the arm matching how this product is used is the arm that got worse. It is cell culture and has never been followed into a mammal. The cheapest human readout sensitive to a hepatic mitochondrial problem is a CMP with GGT at baseline and twelve weeks: a rise is not proof and a flat result is not safety, but it is the only measurement anybody is realistically going to take, and nobody currently takes it.

What nobody has tested yet

Five experiments nobody has run. The first two would settle what this product actually is, and both are cheap.

1. The head-to-head: acid versus amide, same assay, same afternoon. Chyan 1999 measured the acid's hydroxyl-radical scavenging against melatonin in kinetic competition. Nobody has put the amide through that assay, and Jasiewicz 2021 is the reason it matters — across fifteen C-3 substituted indoles, activity depended strongly on the substituent at exactly the position that differs here. Both molecules keep the free indole NH that paper calls mandatory; only the terminal group differs. The answer decides whether the antioxidant claim on the label transfers at all.

2. Does an oral amide dose raise the acid in a mammal? One time course in rats, plasma IPA against time after oral IPAM. Never published. If the answer is yes, this page's evidence gets orders of magnitude stronger overnight; if no, the product is not what its own name implies.

3. The chronic arm of the cardiac finding, in an animal. Gesper 2021 saw acute benefit and chronic harm in three cell types and stopped there. Nobody has fed a rodent IPA for months and measured cardiac mitochondrial function — the single study separating a longevity molecule from a slow liability, and the one a supplement category has least incentive to fund.

4. Whether the people who respond are the people who are low. The diabetes association is between people, not within them de Mello 2017, and Sehgal 2022 says levels vary hugely and track dietary fiber. If IPA is causal, responders should be the low-fiber, low-IPA end and the high end should get nothing. No study has stratified anything by baseline serum IPA — which also means nobody has run the cheap version of this product, rye Koistinen 2024, against the capsule with serum IPA as the endpoint.

5. Whether IPAM is endogenous in humans at any measurable concentration. Poeggeler 2010 calls it “a novel endogenous indole derivative”, and that word does a great deal of marketing work downstream. A PubTator3 search for the molecule's own name on 10 September 2026 returned that one paper about it as a substance, a handful of untargeted metabolomics studies in which the name merely appears, and nothing establishing a human reference range, a biosynthetic route, or an organism that makes it.

Indolepropionamide — its own safety story, not its class's

The first safety fact is a naming problem, and it is not trivial. IPAM is not Ipamorelin. Ipamorelin is an injected pentapeptide acting at the ghrelin receptor to release growth hormone, with its own page here. Indolepropionamide is an oral small molecule with one 2010 paper in rotifers and isolated mitochondria. Confusing them means the wrong route, the wrong class and the wrong expectation, and four shared letters are the entire reason the mistake is available.

There is no toxicology, in the strict sense. No repeat-dose study, no NOAEL, no genotoxicity panel, in any species, for the amide. The reassurance usually offered — that the acid is a normal human metabolite — is true and is a different claim: something your gut flora produce continuously at whatever concentration they produce it is not evidence about a daily bolus of a chemically distinct analog.

The specific open risk is the acute-to-chronic reversal, and it is unusual because it comes from the mechanism's own best paper. Gesper 2021 found that an apparent mitochondrial benefit on acute exposure became mitochondrial dysfunction on chronic exposure, in cardiomyocytes and again in human hepatic and endothelial cells. That is the wrong direction for something taken daily for months, it is the finding no vendor page will quote, and it has not been resolved in any animal.

A real interaction question, with a named receptor. Venkatesh 2014 establishes IPA as a ligand for the pregnane X receptor — the xenobiotic sensor whose best-known job in humans is driving transcription of the drug-metabolizing machinery that clears a large share of prescription medicines. That paper measured barrier function, not drug clearance, and reported no interaction, so what exists is a mechanistic route rather than an observed effect. Anyone on a medicine with a narrow therapeutic index should want that answered rather than assumed; for either molecule, it has not been asked.

You cannot verify what you bought. The two molecules sit 0.984 Da apart, and the amide's ¹³C peak sits 0.019 Da from the acid's monoisotopic peak, so a nominal-mass certificate reading “189” distinguishes nothing. High-resolution MS or an NMR would. Nobody in this category publishes either.

The most likely harm here is not toxicity, it is substitution. The strongest evidence attached to this molecule is a 15-year human association in which the exposure was a gut that makes the acid out of dietary fiber de Mello 2017 Sehgal 2022. Buying a capsule instead of changing the diet copies the biomarker rather than the thing the biomarker is reporting on, and that is the failure mode this page exists to name.

Sources read for this page

• Poeggeler B, Sambamurti K, Siedlak SL, Perry G, Smith MA, Pappolla MA. A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan. PLoS One 2010;5(4):e10206 · PMID 20421998
• Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, Pappolla MA. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. Journal of Biological Chemistry 1999;274(31):21937-42 · PMID 10419516
• Jasiewicz B, Kozanecka-Okupnik W, Przygodzki M, Warzajtis B, Rychlewska U, Pospieszny T, Mrowczynska L. Synthesis, antioxidant and cytoprotective activity evaluation of C-3 substituted indole derivatives. Scientific Reports 2021;11(1):15425 · PMID 34326403
• Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, Qiu Z, Maher L, Redinbo MR, Phillips RS, Fleet JC, Kortagere S, Mukherjee P, Fasano A, Le Ven J, Nicholson JK, Dumas ME, Khanna KM, Mani S. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 2014;41(2):296-310 · PMID 25065623
• Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proceedings of the National Academy of Sciences 2009;106(10):3698-703 · PMID 19234110
• Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, Le A, Cowan TM, Nolan GP, Fischbach MA, Sonnenburg JL. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 2017;551(7682):648-652 · PMID 29168502
• de Mello VD, Paananen J, Lindstrom J, Lankinen MA, Shi L, Kuusisto J, Pihlajamaki J, Auriola S, Lehtonen M, Rolandsson O, Bergdahl IA, Nordin E, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Landberg R, Eriksson JG, Tuomilehto J, Hanhineva K, Uusitupa M. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study. Scientific Reports 2017;7:46337 · PMID 28397877
• Sehgal R, de Mello VD, Mannisto V, Lindstrom J, Tuomilehto J, Pihlajamaki J, Uusitupa M. Indolepropionic acid, a gut bacteria-produced tryptophan metabolite and the risk of type 2 diabetes and non-alcoholic fatty liver disease. Nutrients 2022;14(21):4695 · PMID 36364957
• Koistinen VM, Haldar S, Tuomainen M, Lehtonen M, Klavus A, Draper J, Lloyd A, Beckmann M, Bal W, Ross AB, Brandt K, Fawcett L, Seal C, Hanhineva K. Metabolic changes in response to varying whole-grain wheat and rye intake. npj Science of Food 2024;8 · PMID 38291073
• Gesper M, Nonnast ABH, Kumowski N, Stoehr R, Schuett K, Marx N, Kappel BA. Gut-derived metabolite indole-3-propionic acid modulates mitochondrial function in cardiomyocytes and alters cardiac function. Frontiers in Medicine (Lausanne) 2021;8:648259 · PMID 33829028
• Wang G, Wu H, Wang Y, Liu X, Peng S, Wang W, Wu M, Liu Y, Wang E, Wang Z, Xu L, Wang X, Yang W, Chen H, Zhou X, Hou T. Discovery of novel Nav1.7-selective inhibitors with the 1H-indole-3-propionamide scaffold for effective pain relief. Research (Washington DC) 2025;8:0599 · PMID 39881860

Indolepropionamide — interference & stacking

Bloodwork to run alongside Indolepropionamide

Baseline first, then again at 8–12 weeks.

The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.

Check results you already have → · All 103 markers A–Z

Indolepropionamide — frequently asked questions

What Indolepropionamide is used for

Indolepropionamide appears under 1 goal in the goal router.

Related Longevity & Bioregulators compounds

← Explore the full Protocol Vault

↑ Back to on this page